• Miscellaneous dermatological conditions

Hemangeol Generic Name & Formulations

General Description

Propranolol HCl 4.28mg/mL; soln; alcohol-, paraben- and sugar-free; strawberry/vanilla flavors.

Pharmacological Class


How Supplied

Soln—120mL (w. oral syringe, adapter)

Generic Availability


Hemangeol Indications


Proliferating infantile hemangioma requiring systemic therapy.

Hemangeol Dosage and Administration


Not applicable.


Administer directly in mouth during or right after a feeding. May be diluted in small amount of milk or fruit juice, given in a baby's bottle, if needed. 5 weeks–5 months: initially 0.15mL/kg (0.6mg/kg) twice daily at least 9hrs apart. After 1 week, increase to 0.3mL/kg (1.1mg/kg) twice daily. After 2 weeks, increase to 0.4mL/kg (1.7mg/kg) twice daily and maintain dose for 6 months. Readjust dose periodically based on weight increases. May re-initiate if hemangiomas recur. >1yr: not established.

Hemangeol Contraindications


Premature infants (w. corrected age <5 weeks). Infants <2kg. Asthma or history of bronchospasm. Heart rate <80bpm, >1st-degree heart block, or decompensated heart failure. Blood pressure <50/30mmHg. Pheochromocytoma.

Hemangeol Boxed Warnings

Not Applicable

Hemangeol Warnings/Precautions


May mask signs of hypoglycemia. Increased risk of hypoglycemia esp. during poor oral food intake, vomiting, infection, cold, or stress; withhold dose under these conditions; discontinue if hypoglycemia occurs. Bradycardia. Hypotension. Monitor HR and BP for 2hrs after initiation or dose increases. Discontinue if severe (<80bpm) or symptomatic bradycardia or hypotension (SBP <50mmHg) occurs. Interrupt treatment if lower respiratory tract infection develops. CHF. Increased risk of stroke in PHACE syndrome with severe cerebrovascular anomalies; evaluate for potential arteriopathy prior to initiation. Pregnancy, nursing mothers: not indicated.

Hemangeol Pharmacokinetics

See Literature

Hemangeol Interactions


Increased risk of hypoglycemia with concomitant corticosteroids. May interfere with epinephrine. Potentiated by CYP2D6, CYP1A2, CYP2C19 inhibitors. Antagonized by CYP1A2 inducers (eg, phenytoin, phenobarbital) and CYP2C19 inducers (eg, rifampin).

Hemangeol Adverse Reactions

Adverse Reactions

Sleep disorders, aggravated respiratory tract infections (eg, bronchitis, bronchiolitis, cough), diarrhea, vomiting, peripheral coldness, agitation, somnolence; hypoglycemia, bronchospasm.

Hemangeol Clinical Trials

See Literature

Hemangeol Note

Not Applicable

Hemangeol Patient Counseling

See Literature